Several isoforms of human GH (hGH) are produced by two related genes expressed in the pituitary (hGH-N) and in the placenta (hGH-V). These genes consist of five exons (denoted 1-5) separated by four introns (denoted A-D). In the present report, two new transcripts of the hGH-V gene are described. The coding region of the hGH-V gene was amplified by RT-PCR using placental complementary DNA as template. DNA sequencing of several clones revealed two novel transcripts. One had a 45-bp deletion caused by the use of an alternative splice acceptor site within exon 3, similar to that in the hGH-N gene, predicting a 20-kDa isoform of hGH-V. The other transcript was generated by the use of an alternative splice donor site causing a 4-bp deletion in the end of exon 4, predicting a 24-kDa protein with 219 amino acids, which we refer to as hGH-V3. The carboxy-terminal sequence of hGH-V3 differs from 22-kDa hGH-V and hGH-V2, the two previously reported transcripts of the hGH-V gene, and does not contain a predicted transmembrane domain as described for hGH-V2.
T HE human GH (hGH) gene cluster is located on the long arm of chromosome 17 and consists of five highly sequence-conserved genes aligned in the same transcriptional orientation. Among these genes, the hGH-N (N ϭ normal), which is expressed in somatotrophic cells of the anterior pituitary, and the hGH-V (V ϭ variant), which is expressed in syncytiotrophoblastic cells in the placenta, are responsible for the production of different hGH isoforms. In these genes, five exons (designated 1 to 5) are separated by four introns sequences (designated A to D) (1) (2) (3) (4) (5) .
In the pituitary, the major product of the hGH-N gene is a single chain polypeptide with 191 amino acids and a molecular mass of approximately 22-kDa (6) , which is an important regulator of postnatal growth and metabolism (7, 8) . Approximately 10% of the hGH-N transcripts in the pituitary use an alternative splice acceptor site resulting in the 20-kDa hGH isoform of the hGH-N, in which amino acids 32-46 of the 22-kDa hGH-N are deleted (9) . The 20-kDa hGH-N shows some differences regarding biological activities, binding affinity, and clearance from blood compared with hGH-N (9 -13). However, both 22-kDa and 20-kDa hGH-N are capable of promoting growth (9, 14) . The hGH-V gene encodes a 22-kDa hGH-V isoform, which differs from the 22-kDa hGH-N by 13 amino acids in positions dispersed throughout the mature secreted hormone (15) . The 22-kDa hGH-V also undergoes glycosylation to yield a 25-kDa isoform (16, 17) . The physiological role of 22-kDa hGH-V is unclear, but it progressively replaces 22-kDa hGH-N in the maternal circulation during pregnancy (18, 19) . Placental and pituitary 22-kDa hGH show similar somatogenic activity, but the placental isoform has reduced lactogenic activity (20) . In contrast with the hGH-N gene, the use of the alternative splice site generating a 20-kDa isoform has not been documented for the hGH-V gene (21, 22) . Instead, a different splicing pathway in which intron D is retained in the processed messenger RNA (mRNA) has been identified, predicting a 230-amino acid protein called hGH-V2. This 26-kDa isoform of the hGH-V gene shows complete sequence divergence in the carboxy-terminus compared with 22-kDa hGH-V, and it is presumably a membrane-bound protein (23) .
In this study, two new transcripts of the hGH-V gene are described. One of the transcripts uses the same alternative splice acceptor site within exon 3, as seen in the hGH-N gene (9) , predicting a 20-kDa isoform of the hGH-V gene. The other transcript, which we refer to as hGH-V3, is generated by the use of an alternative splice donor site near the end of the fourth exon causing a 4-bp deletion. The hGH-V3 tran-script predicts a 24-kDa protein with 219 amino acids, in which the first 124 amino acids are identical to those of placental 22-kDa hGH, whereas the remaining carboxyterminal residues shows a complete sequence divergence.
Material and Methods

Cloning of GH-V complementary DNAs (cDNAs)
hGH-V cDNA was amplified by nested PCR using a human placental cDNA library as template. The outer primers were hGHV-S1 and hGHV-S2, and the inner primers were hGHV-S3 and hGHV-S4, as shown in Table 1 . Amplification was done in 50 mmol/L KCl, 20 mmol/L TrisHCl (pH 8.4), 1.5 mmol/L MgCl 2 , 200 mol dNTPs, 50 pmol of each primer, and 2 U Taq polymerase in a total volume of 50 L, using the GeneAmp PCR system 9600 (Perkin-Elmer/Cetus, Norwalk, CT). In the first PCR reaction using primers hGHV-S1 and hGHV-S2, denaturation at 95 C for 5 min was followed by 32 cycles of amplification with denaturation at 94 C for 1 min, annealing at 57 C for 1 min, and extension at 72 C for 1 min, with an extension time increase of 5 sec/cycle. The PCR products were diluted 1:1000, and 1 L was used as template for amplification with primers hGHV-S3 and hGHV-S4, following the same PCR-profile, with the exception that the annealing temperature was increased to 62 C. The PCR products were separated on 1% agarose gels and purified using the Geneclean II kit (Bio 101, Vista, CA) before restriction analysis or subcloning into pCR-II (Invitrogen, San Diego, CA). Subcloned PCR products were sequenced using the PRISM Sequenase terminator single-stranded DNA sequencing kit (Applied Biosystems, Foster City, CA).
RNA preparation
Total RNA was isolated from pathological and normal placentas using RNA STAT-60 (Tel-Test B, Friendswood, TX), essentially as described by Chomczynski and Sacchi (24) .
Amplification of cDNAs encoding hGH-V, hGH-N, and human chorionic somatomammotropin (hCS)-A/B
First-strand cDNA was generated using 2 g total placental or pituitary RNA as template, in the presence of RT buffer [50 mmol/L Tris-HCl (pH 8. Table 1) . A schematic representation of the location of the primers used in the reactions is shown in Fig. 1 . Sequences containing parts of 22-kDa hGH-V (125 bp), 20-kDa hGH-V (118 bp), or the full-length 22-kDa hGH-V (648 bp) were PCR amplified from human placental cDNA using a common forward primer (PO11) and three different reverse primers, the hGH-V-22K, located within exon 3, the hGH-V-20K, which was designed to bridge nucleotides encoding amino acids 31 and 47 of the hGH molecule, and the PO12, located in the 3Ј-untranslated region of the hGH-V mRNA ( Fig. 1 ). hCS-A/B (388 bp) was amplified from human placenta cDNA using primers hCS1 and hCS2. hGH-N was amplified using primers FGH1A and FGH2B with human pituitary cDNA (Clontech, Palo Alto, CA) as template, resulting in a PCR product containing 573 bp. PCR amplifications were carried out using the GeneAmp PCR system 9600 (Perkin-Elmer/Cetus; 30 sec denaturation at 94 C, 15 sec annealing at 57 C, and 40 sec elongation at 72 C; 35 cycles). Aliquots of the amplified samples were separated on a 1% agarose gel, and the PCR products were purified using the the Geneclean II kit (Bio 101). sec at 60 C) in the GeneAmp PCR system 9600 (Perkin-Elmer/Cetus). The reactions were stopped by adding loading dye containing formamide. The LCR products were separated on 6% polyacrylamide gels and analyzed by the Phosphor Imager (Molecular Dynamics; Sunnyvale, CA). The size of the LCR products was compared with radiolabeled size markers (Promega).
Ligase chain reaction (LCR)
LCR
Competitive PCR assay
To estimate the relative proportions of the new transcripts in relation to the total hGH-V mRNA, competitive PCRs for 20-kDa hGH-V and hGH-V3 were performed using primers PO11/PO14 and GHV3A/ GHV3B, respectively (Table 1 and Fig. 1 ). The forward primers were end-labeled in a reaction similar to that described for the LCR primers.
Competitive PCR was performed with placental cDNA as template (20 sec at 94 C, 15 sec at 57 C (20-kDa hGH-V) or 60 C (hGH-V3), and 30 sec at 72 C; 35 cycles). The PCR products were electrophoresed on 6% polyacrylamide gels, and the bands were visualized and quantified by the Phosphor Imager (Molecular Dynamics). 
Hydrophilicity plots
The hydrophilicity plots (scale Kyte-Doolittle) of 22-kDa hGH-V, hGH-V2, and hGH-V3 were obtained using the software MacVector version 4.5 (Eastman Kodak, Rochester, NY).
Results
Identification of novel hGH splice variants in human placenta
A scheme of the splicing mechanisms of hGH-V gene is shown in the Fig. 2A . Sequencing of several clones obtained by PCR of the coding region of the hGH-V gene using human placental cDNA as template revealed two novel transcripts.
One of the transcripts had a 45-bp deletion within exon 3, similar to that described in the hGH-N gene, predicting a 20-kDa isoform of hGH-V (GeneBank accession number: AF006060). Using RT-PCR and primers PO11 and hGHV-20K, which were designed for specific amplification of placental 20-kDa hGH-V, a DNA fragment of 118 bp was identified (data not shown). The other new transcript, designated hGH-V3, resulted from the use of an alternative splice donor site near the end of exon 4, causing a deletion of 4 bp (GTGG) upstream of the regular splice site (GeneBank accession number: AF006061). The hGH-V3 transcript is predicted to encode a 24-kDa protein with 219 amino acids (245 with the signal peptide) with a frameshift after residue 124 compared with placental 22-kDa hGH. This alternative splice donor site is not present in either hGH-N or hCS-A/B because of a nucleotide difference in the sequence of these genes (GGGG instead of GTGG) (Fig. 2B) .
LCR was then used to analyze the use of the same splicing pattern in transcripts derived from the other genes of the hGH-gene cluster. The LCR products of 50 bp corresponding to transcripts encoding the 20-kDa isoforms of hGH-N and hGH-V were detected in hGH-N cDNA and in hGH-V cDNA, respectively, but not in hCS-A/B cDNA (Fig. 3) . In addition, the 50-bp band corresponding to hGH-V3 transcript was only observed in placental cDNA from the hGH-V gene, but not in cDNAs derived from the other genes of the cluster (Fig. 3) .
Expression of new transcripts in human placenta
The expression of the new transcripts in relation to the total hGH-V mRNA was estimated by competitive PCR in four full-term normal placentas and three placentas from pregnancies with complications. A diagram showing the location of the primers used in the competitive PCRs is shown in Fig.  4A . The expression of hGH-V3 did not vary greatly in normal and pathological placentas, corresponding to approximately 10% of the hGH-V transcripts. The 20-kDa hGH-V mRNA was only detected in two of the four normal placentas, and a weak signal was observed in one of the abnormal placentas (Fig. 4B) .
Hydrophilicity of hGH-V3
The predicted proteins encoded by the hGH-V2 and hGH-V3 transcripts have distinct carboxy-termini compared with other hGH isoforms (Fig. 5) . The hGH-V3 is a 24-kDa protein with 219 amino acids, in which the first 124 amino acids are identical to those of 22-kDa hGH-V, with a frameshift occurring in the remaining carboxy-terminal sequence. In this part of hGH-V3, there is no transmembrane domain, as predicted for the hGH-V2 (23) (Fig. 6) .
Discussion
Sequence analysis of several hGH-V cDNA clones revealed the presence of two novel transcripts of this gene, in addition to those two previously described encoding 22-kDa hGH-V (27, 28) and hGH-V2 (23) . One of the novel transcripts predicts a 20-kDa hGH-V isoform, generated through the use of an alternative splice site similar to that described for the hGH-N gene (9, 29, 30) . The other novel transcript, hGH-V3, uses an alternative splice donor site near the end of exon 4 of the hGH-V gene, only 4 bp upstream of the regular splicing site. hGH-V3 mRNA is predicted to encode a 24-kDa protein with 219 amino acids and an unique carboxy-terminus. In our study, LCR products corresponding to 20-kDa hGH-V
FIG. 2. Schematic representation of hGH-V gene and its alternative spliced products. A, hGH-V gene with its five exons (1-5) and four introns (A-D) is shown in upper part of diagram.
Most common splicing mechanism of hGH-V primary transcript removes all intron sequences resulting in 22-kDa hGH-V mRNA. Twenty-kilodalton hGH-V mRNA is generated by use of an alternative splice site within exon 3, which eliminates codons for amino acids 32-46, similar to that described for hGH-N. In hGH-V2 mRNA, intron D is retained in processed mRNA, resulting in frameshift. hGH-V3 mRNA is produced by use of an alternative splice site near end of exon 4, predicting a protein with a unique carboxyterminus. Right arrows in hGH-V2 and hGH-V3 transcripts denote sequence divergence carboxy-terminal to splice site. *, In hGH-V3 indicates sequence after exon 5 that is translated in this isoform. B, Characterization of hGH-V3 (left) and 20-kDa hGH (right) mRNA splicing of hGH-V gene. Consensus sequences for splice donor and acceptor sites are shown. Bold type indicates highly conserved bases. Predominant splicing site is indicated by solid lines, and alternative splicing sites is indicated by dotted lines. In hGH-V3 mRNA, alternative site is located only 4 bp upstream of normal splice donor site (GTGG, in italics). Note T to G transition present in hGH-N and hCS-A/B genes.
and hGH-V3 were detected by oligonucleotides that were correctly base-paired at the junction in both transcripts, using placental cDNAs as template. As expected, the 20-kDa hGHtranscript was also detected in cDNA derived from the hGH-N gene, but not in cDNA derived from the hCS-A/B genes. In contrast, the alternative splice pattern generating hGH-V3 mRNA was only observed in transcripts derived from the hGH-V gene.
Although the hGH-V gene is highly similar in structure to the hGH-N gene, processing of its primary transcript has not been shown to use the alternative acceptor site that generates pituitary 20-kDa hGH. Instead, transfection studies using genes encoding hGH-N, hGH-V, or chimeric genes, have identified striking differences between hGH-N and hGH-V genes regarding the use of this acceptor site (21, 31) . Sequences in the immediate proximity of the alternative splice acceptor sites, as well as more remote sequences, seem to contribute to the splice site selection (22) . Our results using placental cDNA as template show that primary transcripts derived from the hGH-V gene can be alternatively spliced within exon 3 in a manner similar to that observed for the hGH-N gene. The expression of the placental 20-kDa hGH transcript seems to vary among different full-term normal placentas and placentas with abnormalities. In fact, the transcript encoding 20-kDa hGH-V was not detected in all placentas. This variation in expression of the 20-kDa hGH-V transcript might partly explain the previous unsuccessfully attempts in detecting this transcript (21) . Interestingly, altered hGH/hCS gene expression has been described in human trophoblastic neoplasms in comparison with normal placentas (32) , and further studies are needed to address whether the expression of various transcripts differs under physiological or pathological conditions.
In contrast to the transcript encoding 20-kDa hGH-V, the hGH-V3 transcript seems to be expressed in similar amounts in different placentas, comprising approximately 10% of the total hGH-V transcripts. However, it is unclear whether the abundance of these transcripts reflects the production of the predicted proteins. The alternative splice site generating hGH-V3 is not present in the other genes of the cluster. This is probably because of a T to G transition observed in the splice donor site of the other genes that presumably prevents this splicing in the hGH-N and hCS-A/B genes. Interestingly, the predicted hGH-V3 protein exhibits a complete frameshift carboxy-terminal to the splice site, similar to what is observed in hGH-V2 (23) and bovine GH (33) . However, in contrast to hGH-V2, there was no putative transmembrane domain in the carboxy-terminus of the predicted hGH-V3 protein as analyzed by hydrophilicity plots. The predicted hGH-V3 protein is a member of a group of GH-related proteins with distinct carboxy-terminal, which includes hGH-V2 and bovine GH (23, 33) .
The interaction between hGH and its receptor is a sequential event, in which hGH initially binds to one hGH receptor (hGHR) molecule through a large contact surface area (site 1), involving amino acids of the carboxy-terminal part of the fourth helix bundle, to form an inactive 1:1 complex. This complex then associates with a second hGHR molecule via binding to site 2, which represents a smaller surface area on the N-terminal part of the hGH molecule (34, 35) . The distinct carboxy-terminus in the predicted hGH-V2 and hGH-V3 proteins completely changes the amino acids in binding site 1. Thus, it remains to be elucidated if these new hGH isoforms are able to bind and activate the hGHR (36). Alternatively, it is possible that hGH-V3 and related molecules act through specific receptors, as suggested for other hGH and human PRL fragments (37, 38) and more recently, for 22-kDa hGH-V (39) .
The role of placental hGH-V is unclear, but there are indications that it may participate in the regulation of maternal metabolism (40) . The 22-kDa hGH-V levels are reduced in most cases of intrauterine growth retardation in comparison with normal pregnancies (41) . Moreover, hGH-V2 is probably a membrane-bound protein, and its expression is controlled independently from the expression of 22-kDa hGH-V during gestation, supporting the idea that hGH-V and related peptides play a role in placental growth or function (42, 43) . The results of the present study showing that the hGH-V primary transcript undergoes alternative splicing generating at least four different mRNAs, two of them predicting proteins with completely distinct carboxy-termini, add new complexity to the physiology of hGH during pregnancy. 
